Changing the Course of Drug Shortages

AdobeStock_407342778_Rawpixel.com

Drug shortages were a major concern before the COVID-19 pandemic, which only served to further add pressure to an imperfect supply chain. The COVID-19 pandemic placed added pressure on bio/pharma’s imperfect supply chain, contributing to ongoing drug shortages and creating some new challenges. What has the industry learned from the pandemic and will practices and supply-related decisions change going forward?

Regulatory Sourcebook

Read this article in Pharmaceutical Technology's September 2021 Regulatory Sourcebook.

About the author

Meg Rivers is a senior editor at Pharmaceutical Technology, Pharmaceutical Technology Europe, and BioPharm International.

Article Details

Pharmaceutical Technology
eBook: Regulatory Sourcebook, September 2021
September 2021
Pages: 16-22

Citation

When referring to this article, please cite it as M. Rivers, “Changing the Course of Drug Shortages," Pharmaceutical Technology Regulatory Sourcebook eBook (September 2021).